Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$316.50 USD

316.50
623,669

+8.57 (2.78%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Indrajit Bandyopadhyay headshot

Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More

by Indrajit Bandyopadhyay

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this time.

McKesson (MCK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for West Pharmaceutical (WST) in Q3 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and bottom lines.

West Pharmaceutical Services (WST) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

West Pharmaceutical's (WST) Latest Investment to Boost Business

by Zacks Equity Research

West Pharmaceutical's (WST) minority investment is expected to aid in meeting patients' continuously evolving needs of ease of use and effective methods of medicine delivery.

West Pharmaceutical (WST) Q2 Earnings Beat, FY22 View Cut

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter earnings reflect strength in the Proprietary Products segment.

West Pharmaceutical Services (WST) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 12.79% and 2.44%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.

West Pharmaceutical Services (WST) is a Top-Ranked Growth Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

West Pharmaceutical's (WST) Syringe System to Improve Outcome

by Zacks Equity Research

West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Why Is AmerisourceBergen (ABC) Down 4.5% Since Last Earnings Report?

by Zacks Equity Research

AmerisourceBergen (ABC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why West Pharmaceutical Services (WST) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

West Pharmaceutical (WST) Q1 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

West Pharmaceutical's (WST) first-quarter earnings reflect strength in the Proprietary Products segment and operating margin expansion.

West Pharmaceutical Services (WST) Q1 Earnings Top Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 5.50% and 0.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for West Pharmaceutical's (WST) Q1 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) first-quarter results are likely to reflect strength in the Proprietary Products business.

West Pharmaceutical Services (WST) is a Top-Ranked Growth Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Reasons to Add AMN Healthcare (AMN) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare (AMN) on its broad array of services.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Zacks Industry Outlook Highlights McKesson, West Pharmaceutical Services and Cardinal Health

by Zacks Equity Research

McKesson, West Pharmaceutical Services and Cardinal Health have been highlighted in this Industry Outlook article.

    West Pharmaceutical Services (WST) Outpaces Stock Market Gains: What You Should Know

    by Zacks Equity Research

    West Pharmaceutical Services (WST) closed at $414.12 in the latest trading session, marking a +1.84% move from the prior day.